AVPL drones keep water bodies pest-free
The initiative covered a total area of 3 acres over a two-day operation, marking the beginning of a year-long project aimed at comprehensive mosquito control in the region. A medium-category drone equipped with a centrifugal nozzle was used for the spraying, ensuring precise application of the larvicide while minimising human exposure and maximising coverage. The operations were conducted by a team comprising 2 pilots, trained and certified by AVPL's DGCA-approved Remote Pilot Training Organisation (RPTO). Speaking about the initiative, Preet Sandhuu, Founder and MD of AVPL International, said, 'It is an honor to work towards this transformative public health and safety initiative. At AVPL, we are deeply committed to serving the nation, whether by nurturing talent or safeguarding communities for societal benefit.'
The use of drone technology to treat inaccessible water bodies, was a success ensuring comprehensive coverage and leaving no mosquito breeding grounds untreated. This targeted approach aims to significantly reduce the spread of vector-borne diseases like dengue and malaria, creating a safer and healthier environment for Hyderabad's residents.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 days ago
- Time of India
Oligonucleotides: The Tiny Molecules, Reshaping Modern Medicine
Diseases, not just treated but edited out. Oligonucleotide therapies are making it possible. Imagine if doctors could fix a disease by correcting the problem in your DNA, like editing a sentence in a book. That's not science fiction anymore. It's happening today with a new kind of treatment called oligonucleotide therapy. These treatments don't just treat symptoms like fever or pain. Instead, they go to the root cause of your genes and try to fix what's wrong. What Are Oligonucleotide therapies? Oligonucleotides (we'll call them short DNA or oligos) are tiny man-made pieces of genetic material, like DNA or RNA. They are manufactured in a laboratory and are used to send special messages inside the body's cells. These messages can help turn off harmful genes, repair damaged ones, or change how they work. Oligonucleotide therapies come in different types, like antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers. Each type works a bit differently, but they all aim to fix faulty genetic messages inside our cells. Depending on the type of oligo, they act in different ways: Block harmful proteins: Some oligos stick to bad RNA and stop it from making harmful proteins. Destroy faulty messages: Others call in the body's enzymes to break down the bad RNA before it can do damage. Fix genetic mistakes: Some oligos help the body 'edit' or 'splice' RNA properly, correcting how a gene message is read. In short, oligo therapies are smart medicines that repair the body's internal instructions. How Are They Helping People? In recent years, oligos have been used to treat some very serious illnesses, especially those caused by faulty genes. Some real-world U.S. FDA-approved examples include: Spinraza: Helps children with spinal muscular atrophy (SMA) walk and breathe better. Exondys 51: Used for Duchenne muscular dystrophy (DMD) to help muscles stay stronger for longer. Tofersen: Approved to treat a rare genetic form of ALS, a nerve disease. Olezarsen: A new drug that treats a rare condition where fat levels in the blood become dangerously high. Qfitlia: Approved to treat Hemophilia A or B, with or without inhibitors, the first and only such treatment of its kind. More are on the way. Over 30 oligo-based treatments are being tested in clinical trials for diseases like cancer, heart problems, blood disorders, and even rare brain conditions. Offer new hope for patients with serious genetic diseases. Why Oligonucleotides Are a Game-Changer in Drug Development? Here's why experts believe oligonucleotides are changing the future of medicine: Super-Targeted Treatment: These medicines work like a GPS. They find and fix specific genetic problems without affecting the rest of the body. This means more effective treatment and fewer side effects. Quick to Develop: Oligonucleotide drugs can be made faster than traditional medicines because they follow a simpler design. This helps scientists respond more quickly, especially during health emergencies or for rare diseases. Fewer Side Effects: Since they only act on the problem area, they're often safer and easier on the body. Many patients tolerate them well. Work Even in Small Doses: These medicines are powerful. Just a small amount can be enough to get the job done, reducing the need for heavy doses. Can Treat Many Illnesses: From rare genetic disorders and cancers to viral infections like hepatitis, oligonucleotide therapies can be used for a wide range of diseases. This makes them very versatile. Fixes Problems at the Gene Level: Unlike other drugs that just manage symptoms, oligonucleotides can turn off faulty genes, fix how genes are read, or stop harmful proteins from forming. Better Technology Means Better Results: With new ways to deliver these drugs into the body and protect them from breaking down, they are now more stable, more accurate, and more effective. Challenges Ahead: Despite their potential, oligonucleotide therapies face several significant hurdles: High development and manufacturing costs Complex regulatory approval processes Limited public and clinical awareness There is a need for specialized delivery systems to reach target tissues. Their large molecular size prevents easy entry into cells, requiring innovative delivery approaches such as inhalable aerosols or nano formulations. These methods are less invasive than monoclonal antibodies and may also reduce adverse effects like hypersensitivity reactions. Currently, over 30 second-generation antisense oligonucleotides (ASOs) are in clinical trials for neurological, cardiovascular, metabolic, and cancer-related conditions. However, challenges such as short half-life, rapid clearance, and inefficient cellular uptake persist. Advanced solutions, like lipid- or polymer-based nanoparticles and ligand-conjugated oligos, are actively being developed to overcome these barriers. While trials for chronic respiratory diseases remain limited, the FDA's approval of oligo-based drugs for disorders like spinal muscular atrophy and Duchenne muscular dystrophy marks a major step forward. Ongoing research into chemical modifications and synergistic combinations is focused on enhancing stability, reducing toxicity, and improving targeted delivery. These challenges also present strategic opportunities. With investments in biotech infrastructure, workforce training, and public–private partnerships, India is well-positioned to become a global leader in oligonucleotide therapeutics. Why India Should Pay Attention: While most approved oligo therapies have emerged from biotech giants in the US and Europe, India has significant potential to emerge as a hub for research, development, and manufacturing in this field. India already houses a growing ecosystem of biotech startups, academic research labs, and genetic testing companies. Our country's strength in cost-effective synthesis of oligonucleotides (used in diagnostics, sequencing, and therapeutics) positions us well for expansion into therapeutics. Imagine an India where advanced gene therapies are not just imported at high prices, but developed locally, affordably, and ethically. The Road Forward: The science of oligonucleotide therapies is still young but advancing rapidly. From rare genetic diseases to common cancers, the potential applications are vast. Global momentum is building, and India must not be left behind. By supporting genomics education, building strong research ecosystems, and encouraging regulatory innovation, we can move from being importers of advanced therapies to becoming innovators and exporters. Artificial Intelligence is further accelerating this progress. From AI-powered design of oligonucleotides to predictive models for delivery and efficacy, smart algorithms are helping scientists develop safer, more precise, and faster therapies. For millions of patients waiting for real cures, these tiny molecules carry huge hope. Bangalore-based Barcode Biosciences, a trusted manufacturer of high-quality oligonucleotides for biopharma, research, and diagnostics laboratories across India, the Middle East, and beyond, is planning to step into GMP-grade therapeutic oligo production in near future, empowering pharma and driving the next wave of transformative treatments. Author: Dr. Ramprasad Kuncham, Scientist, Managing Director & CEO of Barcode Biosciences, is driving India's genomic advancement through expertise in oligonucleotide synthesis, pioneering the launch of the nation's first end to end gene synthesis , and sequencing services "Get the latest news updates on Times of India, including reviews of the movie Coolie and War 2 ."
Economic Times
3 days ago
- Economic Times
Canada to require medical exams for Express Entry Permanent Residence applicants starting August 21
Agencies Starting August 21, 2025, Canada's immigration department will require applicants applying for permanent residence through the Express Entry system to complete medical exams before submitting their applications. This new rule was announced by Immigration, Refugees, and Citizenship Canada (IRCC). Previously, applicants submitted their full permanent residence applications first and waited for IRCC's instructions to complete any medical exams. However, from the new date onwards, the medical exam must be done upfront. This change applies only to Express Entry permanent residence applications. Applications submitted before August 21, 2025, and other types of permanent residence applications are not affected. Medical eligibility criteria Applicants and their family members must be medically admissible to Canada to qualify for permanent residence. This includes family members even if they are not accompanying the principal applicant.A common reason for medical inadmissibility is if an applicant's health condition is expected to cause an excessive demand on Canada's public health services. IRCC defines excessive demand as costs exceeding three times the national average healthcare cost per person, currently set at $27,162 per such as chronic illnesses, like diabetes, are less likely to cause inadmissibility if they are stable and properly treated. Applicants can also be found inadmissible if they have certain infectious diseases posing a public health risk. Immigration medical exam process Medical exams must be conducted by IRCC-approved panel physicians. Applicants can find a list of these doctors on the IRCC website, select their country, and book an appointment exam cost generally ranges from $140 to $280 per person. Applicants must also cover any additional fees for tests, treatments, or specialist exam typically includes: Review of medical history (surgeries, chronic illnesses, treatments) Full physical examination (heart, lungs, eyes, etc.) Chest X-rays to check for diseases like tuberculosis Blood and urine tests Mental health assessments Verification of immunization records Applicants should bring identification documents, four recent photos, medication lists, medical reports, and vaccination proof to their exam. Using previous medical exams Applicants already in Canada who had a medical exam for work or study permits within the last five years can provide their medical exam number when applying for permanent residence. If IRCC finds that previous exam results are not acceptable for permanent residence, the applicant will be asked to undergo a new medical exam. (Join our ETNRI WhatsApp channel for all the latest updates) Elevate your knowledge and leadership skills at a cost cheaper than your daily tea. Regulatory gray area makes investing in LVMH, BP tough For Indian retail How IDBI banker landed plush Delhi properties in Amtek's INR33k crore skimming As 50% US tariff looms, 6 key steps that can safeguard Indian economy Jane Street blow pushes Indian quants to ancient Greek idea to thrive Stock Radar: Astra Microwave showing signs of bottoming out after 16% fall from highs; time to buy? F&O Radar | Deploy Broken Wing in Paytm to play stock's bullish outlook These 9 banking stocks can give more than 28% returns in 1 year, according to analysts Why 2025 Could Be The Astrological Turning Point We've Been Waiting For
&w=3840&q=100)
Business Standard
3 days ago
- Business Standard
Canada Express Entry: PR applicants need mandatory upfront medical exam
Planning to move to Canada via Express Entry? The rules have just got tougher. Starting August 21, 2025, skilled worker immigration applicants will be required to complete a medical exam before submitting their permanent residence application. The change applies to all applicants and their family members, even those not moving to Canada, and replaces the current process where the medical exam is scheduled only after Immigration, Refugees and Citizenship Canada (IRCC) provides instructions. 'From August 21, 2025, proof of a completed Immigration Medical Exam will have to be uploaded into the Express Entry Profile Builder at the time of application,' IRCC confirmed. What is changing Under the new rules, anyone who receives an invitation to apply (ITA) for permanent residence through Express Entry must: • Complete an Immigration Medical Exam (IME) with an IRCC-approved panel physician • Upload proof of the completed IME when submitting their PR application • Ensure each family member, whether accompanying or not, also completes the IME Who can be exempt • Applicants already in Canada who completed an IME in the past five years, for example for a work or study permit, may reuse those results if still valid • They must provide the IME number or unique medical identifier in their application • If the results cannot be reused, IRCC will give further instructions What the Immigration Medical Exam involves The IME is carried out only by IRCC-approved panel physicians and is valid for 12 months. Depending on age and health, it may include: • A physical assessment of overall health • Blood and urine tests for infectious diseases and other conditions • A chest X-ray, usually required for adults to check for tuberculosis or lung problems • A review of medical history, including past and current conditions and medications • Vaccination records, if the applicant consents If an application is not finalised within 12 months of the exam, a new IME may be required. What to bring to your appointment When attending the medical exam, you must carry: • Proper identification — preferably your passport, though other accepted ID includes: 1. A national identity card 2. A driver's licence from Australia, Canada, New Zealand, United Kingdom, or United States (if still in that country) 3. An original birth certificate for children under 18 4. A refugee travel document, Red Cross travel document, UN laissez-passer, seaman's book, Organisation of American States travel document, or refugee protection identity document • Eyeglasses or contact lenses, if used • Any medical reports or test results for previous or existing conditions • A list of current medications • The Medical Report form (IMM 1017E or IMM 1020E) if you have not done an upfront medical exam — this is sent by IRCC • Four recent photographs if the panel physician does not use eMedical (check with the physician beforehand) What you need to pay for Applicants must pay all costs related to the exam, including: • The doctor or radiologist's fee • Any special tests or treatments required • Consultations with specialists, if needed • Optional vaccines offered by the panel physician (fees depend on the physician and local rules) IRCC will not refund these costs if the application is refused. Refugees and asylum seekers may be exempt from paying for the medical exam or vaccines. If you can't complete the exam If you or a family member cannot complete the medical exam — either due to exceptional circumstances or because there is no panel physician in your region — you must submit a letter of explanation. IRCC will review requests on a case-by-case basis. Applicants can contact IRCC by using the online form (select 'Add a document to your application') or through the call centre.
